2seventy bio (TSVT) AI Stock Analysis

• Market Cap: $266.15M
• Dividend Yield: N/A
• Average Volume (3M): 1.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.42
• Revenue Growth: -32.07%
• EPS Growth: 98.22%
• Country: US
• Employees: 65
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 53,229,790
• 10 Day Avg. Volume: 955,203
• 30 Day Avg. Volume: 1,051,216
• PEG Ratio: -0.11
• Price to Book (P/B): 1.23
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.02
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $5.00
• Price Target Upside: 0.00%
• Rating Consensus: Hold
• Number of Analyst Covering: 2

• Rating: 41 Neutral
• Price Target: $5.00 ▲(0.00%Upside)

The overall stock score for TSVT is primarily hindered by poor financial performance and valuation metrics. While technical indicators suggest some market momentum, significant corporate events such as the recent merger and delisting exacerbate the company's challenges. The high financial leverage and operating losses overshadow the stock's prospects, resulting in a low overall score.

Positive Factors

Acquisition Premium

The acquisition of 2Seventy Bio by Bristol-Myers Squibb implies an 80% premium to the previous closing price, boosting investor confidence.

Cash Position

2Seventy Bio ended the quarter with $192 million in cash, providing a solid financial base and extending its cash runway beyond 2027.

Negative Factors

Market Uncertainty

Market uncertainty persists with the expected launch of a third BCMA CAR-T by competitors, posing a threat to Abecma's market position.

Revenue Challenges

2Seventy's top-line revenue fell short of expectations, highlighting challenges in capturing anticipated profits from Abecma.

2seventy bio Business Overview & Revenue Model

Company Description

2seventy bio (TSVT) is a biotechnology company focused on the development and commercialization of innovative cell therapies for the treatment of cancer. Operating in the biopharmaceutical sector, 2seventy bio is dedicated to advancing its pipeline of autologous and allogeneic therapies to improve the lives of patients with serious and life-threatening oncologic diseases.

How the Company Makes Money

2seventy bio primarily generates revenue through the development and commercialization of its pipeline of cell therapies. The company seeks to monetize its therapies via partnerships and collaborations with other pharmaceutical companies and institutions, which can involve upfront payments, milestone payments, and potential royalties from commercial sales. Additionally, 2seventy bio may engage in licensing agreements that allow other companies to utilize its proprietary technologies in exchange for financial compensation. The company's earnings are significantly influenced by the successful research, development, and regulatory approval of its products, as well as the strategic partnerships it forms within the biopharmaceutical industry.

2seventy bio Financial Statement Overview

Summary

2seventy bio is facing significant financial challenges, marked by declining revenues, substantial losses, and high leverage. The company's profitability metrics are under pressure, and cash flow issues persist, indicating the need for strategic realignment and improved financial management to stabilize operations.

Income Statement

The company has experienced declining revenues over the reported periods, with a sharp drop from 2020 to 2024. The gross profit margin remains positive, but the net profit margin is significantly negative, indicating substantial losses. Despite efforts to manage costs, EBIT and EBITDA margins are also deeply negative, reflecting challenges in achieving operational efficiency.

Balance Sheet

The company exhibits a high debt-to-equity ratio, indicating heavy reliance on debt financing. Return on Equity (ROE) has been negative, driven by consistent net losses. Although stockholders' equity has declined, the equity ratio shows a relatively stable position, suggesting some level of asset-backed security.

Cash Flow

Operating cash flow is consistently negative, demonstrating struggles in generating cash from operations. The free cash flow to net income ratio is unfavorable, and the free cash flow growth rate is negative, highlighting cash management challenges. Although investing cash flow has been positive recently, it is overshadowed by the negative operating performance.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
37.86M	100.39M	91.50M	54.52M	248.12M
	Gross Profit
37.86M	83.47M	65.28M	41.93M	242.73M
	EBIT
-115.43M	-216.70M	-262.91M	-313.51M	-144.64M
	EBITDA
-98.45M	-206.42M	-251.38M	-297.16M	-131.45M
	Net Income Common Stockholders
-57.25M	-217.57M	-254.14M	-276.21M	-138.17M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
174.75M	216.99M	266.27M	362.18M	-127.60M
	Total Assets
479.51M	565.43M	656.66M	759.67M	312.62M
	Total Debt
243.72M	256.67M	270.17M	282.21M	127.60M
	Net Debt
172.47M	181.72M	199.14M	151.80M	255.21M
	Total Liabilities
268.70M	310.13M	346.20M	399.85M	237.99M
	Stockholders Equity
210.81M	255.30M	310.47M	359.82M	74.63M
Cash Flow		Free Cash Flow
-85.70M	-180.72M	-259.98M	-226.61M	-90.05M
	Operating Cash Flow
-85.00M	-166.86M	-237.13M	-207.03M	-67.79M
	Investing Cash Flow
80.76M	43.86M	11.70M	15.41M	-22.26M
	Financing Cash Flow
417.00K	127.39M	166.23M	354.89M	90.05M

2seventy bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSVT, the sentiment is Positive. The current price of 5 is above the 20-day moving average (MA) of 4.99, above the 50-day MA of 4.69, and above the 200-day MA of 4.06, indicating a bullish trend. The MACD of 0.09 indicates Positive momentum. The RSI at 72.25 is Negative, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSVT.

2seventy bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TSHA	59 Neutral	$742.75M	―	-159.34%	―	-48.97%	69.32%
ARCT	56 Neutral	$346.87M	―	-27.40%	―	15.40%	35.42%
Sector *	54 Neutral	$5.31B	3.26	-45.10%	2.79%	16.76%	0.02%
RNAC	47 Neutral	$286.41M	―	-938.38%	―	38.82%	-645.78%
AVIR	47 Neutral	$272.14M	―	-30.47%	―	―	-22.66%
OLMA	46 Neutral	$305.16M	―	-41.59%	―	―	0.42%
TSVT	41 Neutral	$266.15M	―	-1.94%	―	-32.07%	98.22%

2seventy bio Corporate Events

2seventy bio Completes Merger, Delists from Nasdaq

On May 13, 2025, 2seventy bio completed a merger that led to significant changes in its corporate structure and stock market presence. The company terminated its 2021 Employee Stock Purchase Plan and Stock Option and Incentive Plan, and requested Nasdaq to suspend trading and delist its common stock. As a result, 2seventy bio’s shares will no longer be listed on Nasdaq, and it plans to terminate its registration and reporting obligations with the SEC. Additionally, the merger resulted in a complete overhaul of the company’s board of directors and executive team, with new appointments including Sandra Ramos-Alves as President and Treasurer.

The most recent analyst rating on (TSVT) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on 2seventy bio stock, see the TSVT Stock Forecast page.

Spark’s Take on TSVT Stock

According to Spark, TipRanks’ AI Analyst, TSVT is a Neutral.

2seventy bio exhibits significant financial difficulties, with declining revenues and persistent losses overshadowing the company’s performance. Technical indicators show strong momentum, but overbought signals could limit further gains. Poor valuation metrics add to the concerns, reflecting the challenges faced by the company amid high volatility.

To see Spark’s full report on TSVT stock, click here.